Company profile
X4 Pharmaceuticals, Inc.
NASDAQ: XFOR · Healthcare · Biotechnology
#485 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
51DFH 48DQ 55GM —SS 56
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$9.0M
Rev growth YoY (TTM)
-71.3%
Net income (FY)
-$79.2M
Employees
45
as of 2026-08-12
Market cap
$403.7M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$35.1M$35.1M2025
Net income-$79.2M-$79.2M2025
Operating income-$86.9M-$86.9M2025
Total assets$290.5M$290.5M2025
Liabilities$104.2M$104.2M2025
Equity$186.3M$186.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY20
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Other Revenue81%
Product19%
By geography
Not disclosed.
The read
What is X4 Pharmaceuticals, Inc.’s revenue?
X4 Pharmaceuticals, Inc. booked $35.1M in FY2025 revenue, growing 1273% year over year — faster than 97% of Healthcare companies we track, at a -225.6% net margin.
Peers · Healthcare
Verrica Pharmaceuticals Inc.51DLeef Brands Inc.57CSenseonics Holdings, Inc.57CPrecision BioSciences, Inc.46DRapid Micro Biosystems, Inc.46DOrchestra BioMed Holdings, Inc.46DNeighbors
Suffolk →Key facts
CEOAdam R. Craig
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: XFOR
Employees45
IPO date2017-11-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.